The current practice in the USA for front-line therapy of driver mutation-negative advanced NSCLC is to treat patients with PD-L1 ≤ 49% (percentage of PD-L1 positive tumor cells by immunohistochemistry) with concurrent chemotherapy plus pembrolizumab, and those with PD-L1 ≥ 50% with pembrolizumab alone or with concurrent chemotherapy. This evidence concerns the gene CD274 and non-small cell lung carcinoma.